Reza Nekouian | Genetics and Molecular Biology | Pioneer Researcher Award

Published on by Citation Awards

Reza Nekouian | Genetics and Molecular Biology | Pioneer Researcher Award

Dr Reza Nekouian, Iran University of Medical Sciences, IUMS, Iran

Dr. Reza Nekouian, a seasoned faculty member at Iran University of Medical Sciences, brings over 17 years of expertise in cancer genetics and molecular diagnostics. Born on March 21, 1978, in Tehran, Iran, he has built a strong reputation in research design, academic teaching, and innovative cancer research solutions. Known for his problem-solving and leadership skills, Dr. Nekouian excels in guiding research teams and translating molecular findings into clinical applications. His academic contributions span across cancer genetics, molecular biology, and personalized medicine. In addition to being a dedicated educator in medical genetics and genetic engineering, he is also widely published in reputable journals. Dr. Nekouian is recognized for his collaborative spirit, exceptional communication, and passion for scientific innovation. His work significantly impacts early cancer detection and personalized treatments, aligning science with real-world health solutions.

Publication Profile

google scholar

Education

Dr. Reza Nekouian received his Ph.D. in Medical Biotechnology from Pune University, India, in 2007, where he specialized in cancer molecular biology and therapeutics. Prior to that, he completed his Master of Science (M.Sc.) in Health Sciences (Genetics) at the University of Pune in 2003. His academic journey reflects a focused pursuit of excellence in biotechnology and genetics, laying the foundation for his later contributions in cancer research and medical education. His studies in India exposed him to a rich scientific environment and equipped him with the latest tools in molecular genetics and biomedical research. These formative years nurtured his deep interest in translational medicine, setting him on a path to combine lab-based innovations with clinical cancer diagnostics. Dr. Nekouian’s educational background continues to fuel his research on biomarkers, cancer therapeutics, and molecular diagnostics, making him a valuable contributor to the global scientific and medical community.

Experience

Dr. Reza Nekouian has served as a faculty member and researcher at Iran University of Medical Sciences (IUMS) since February 2012. His core responsibilities include designing and managing cutting-edge research projects in cancer genetics, molecular diagnostics, and biomarker development for early cancer detection. He also actively contributes to advancing personalized medicine approaches in oncology. As a dedicated educator, Dr. Nekouian teaches theoretical and practical courses in medical genetics and genetic engineering, inspiring the next generation of scientists and clinicians. His professional journey spans over 17 years of impactful work at medical universities and research centers. He is recognized for his skill in resolving complex genetic and molecular research challenges, leading multidisciplinary teams, and publishing groundbreaking findings. With a focus on translational research, he bridges laboratory innovations with patient-centric medical applications, thereby improving diagnostic precision and therapeutic strategies in cancer treatment.

Awards and Honors

Although specific awards are not listed in the profile, Dr. Reza Nekouian’s extensive contributions to cancer genetics, personalized medicine, and molecular diagnostics have earned him academic distinction and professional recognition across Iranian and international research communities. His consistent publication in reputed journals, leadership in high-impact research, and role in educational development underscore his influence in the field. Dr. Nekouian has been instrumental in pioneering research programs and contributing to national strategies for cancer prevention and diagnosis. His invited roles in collaborative projects, advisory panels, and journal editorial activities serve as implicit recognition of his expertise. He is regularly consulted for complex research problem-solving and project development, particularly in molecular biology and biotechnology. Additionally, his leadership in implementing cancer control initiatives in the private health sector highlights his commitment to both scientific excellence and societal health advancement.

Research Focus

Dr. Reza Nekouian’s research centers on cancer genetics, with a specialized focus on the molecular mechanisms of tumorigenesis and biomarker discovery for early detection. His work explores the genetic regulation of cancer progression, using advanced diagnostic tools like circulating microRNAs and liposomal drug delivery systems. He also investigates personalized medicine approaches, including the role of gene expression and polymorphisms in cancer susceptibility and therapeutic response. A recurring theme in his research is the integration of molecular diagnostics with clinical oncology, aiming to improve diagnostic accuracy and treatment precision. Dr. Nekouian has contributed significantly to breast, gastric, and colorectal cancer research, evaluating biomarkers like miRNAs, HLA-G, and FOXP3, and exploring innovative cancer therapies using viral vectors and nanotechnology. His interdisciplinary approach blends molecular biology, bioinformatics, and pharmacogenomics to enhance patient outcomes and reduce cancer mortality through early, personalized interventions.

Publication Top Notes

📄 Evaluation of the in vitro and in vivo effect of liposomal doxorubicin with Newcastle disease virus on 4T1 cell line (2023)
📄 Plasma miR-183-5p as a predictive lymph node metastasis marker in colorectal cancer (2022)
📄 Effect of testosterone enanthate on liver Irs-2 mRNA expression in PCOS model rats (2021)
📄 Meta-analysis of serum HLA-G level accuracy in breast cancer diagnosis (2020)
📄 Expression of angiogenesis-related genes in Iranian breast cancer patients (2020)
📄 Epidemiological study of postsurgical invasive breast cancer cases in Iran (2020)
📄 Use of software in detecting angiogenesis in breast tissue slides (2020)
📄 Meta-analysis of FOXP3 polymorphisms and multiple sclerosis susceptibility (2020)
📄 Evaluation of miR-21 and miR-222 as diagnostic biomarkers for gastric cancer (2019)
📄 Nanocomposite scaffold with MSCs for bone repair applications (2019)
📄 Study on protein-binding malondialdehyde in breast cancer tissues (2019)
📄 Management of biotechnology industry in the West and solutions for Iran (2018)
📄 In vitro effects of Lactobacillus reuteri on gastric cancer progression (2017)
📄 Implementation of private sector cancer prevention programs in Iran (2017)
📄 Study on BRCA1/2 mutations in women with breast cancer family history (2016)
📄 Anti-fibronectin gold nanoparticle biosensor for ECM detection (2014)
📄 Iranian consumers’ shift to functional foods for healthier lifestyle (2014)
📄 FOXP3 mRNA downregulation by Alkanna Frigida extract (2013)
📄 H-semigroup structure on F-offspring of a gene pool (2012)

Siva Vijayakumar Tharumasivam | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Siva Vijayakumar Tharumasivam | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Dr.Siva Vijayakumar Tharumasivam, Dhanalakshmi Srinivasan University, India

Dr. T. Siva Vijayakumar (M.Sc., Ph.D., D.Sc. Honoris Causa) is a dedicated academician and accomplished researcher in Biotechnology, currently serving as Associate Dean – HRDC at Dhanalakshmi Srinivasan University, Tamil Nadu. With a dual role as Flying Officer in the Indian NCC (Airwing), his career embodies leadership in both academia and service. Dr. Vijayakumar’s dynamic research covers aquatic toxicology, nanobiotechnology, neurodegenerative diseases, and regenerative medicine. He has guided numerous students in pioneering scientific exploration and has authored over 48 publications in reputed journals. A passionate mentor, he integrates innovative methodologies in research and education, ensuring his students gain holistic scientific exposure. His expertise has earned national recognition, contributing to scientific knowledge and societal progress. Committed to sustainable solutions, his work addresses pressing environmental and health challenges through nanoscience and biotechnology. His impactful contributions continue to inspire emerging scientists and institutions alike. 🌿🔬🇮🇳

Publication Profile

google scholar

Education

Dr. Siva Vijayakumar pursued his Master of Science (M.Sc.) in Biotechnology, followed by a Doctor of Philosophy (Ph.D.), with an academic journey grounded in molecular biology, toxicology, and applied nanoscience. Recognized for his significant contributions to the field, he was conferred with a Doctor of Science (D.Sc.) Honoris Causa by the International Agency for Standards and Rating in 2021. His education reflects a strong emphasis on multidisciplinary integration, blending core biological sciences with technological innovations. He has continually upgraded his scientific expertise through hands-on research, workshops, and training programs. His educational foundation has enabled him to bridge theoretical knowledge with practical applications in fields such as drug delivery, aquatic environmental health, and regenerative biology. Through his academic pursuits, he has mentored future scientists, instilling a rigorous yet innovative approach to biotechnology. 📘🧬🎓

Experience

Dr. Vijayakumar has over a decade of teaching and research experience in biotechnology. Currently, he holds the position of Associate Dean – Human Resource Development Centre (HRDC) at the Department of Biotechnology, Dhanalakshmi Srinivasan University, Tamil Nadu. He also serves as a Flying Officer and Associate NCC Officer (3TN Air Squadron NCC, Trichy), promoting discipline and patriotism among students. His academic leadership spans curriculum development, research mentoring, and interdisciplinary program coordination. He has played a pivotal role in conducting national workshops, guiding research scholars, and collaborating on funded projects. His administrative experience has fortified institutional growth through strategic planning and research integration. As a faculty member and leader, he’s known for fusing technology with biological sciences, emphasizing innovation, and cultivating global scientific perspectives among students. 🧪📚✈️

Awards and Honors

Dr. Siva Vijayakumar has been honored with several prestigious awards recognizing his excellence in research and education. Notable among them is the Guru Samman Award 2025 🧑‍🏫 by AISPCPA, Bengaluru, and the Innovative Research Award 2023 🧠 by Rover Agricultural College, Perambalur. In 2021, he received the Honorary Doctorate in Biotechnology (D.Sc.) 🎓 and the Research Excellence Award 🏆 by the Institute of Scholars. His early research acumen earned him the Young Investigator Award 2020 🔍 from DERO and the Best Young Scientist Award 2017 🧬 by PEARL Foundation. These accolades reflect his dedication to advancing biotechnology, inspiring students, and contributing meaningfully to scientific society. His recognition across both academic and service domains illustrates a career committed to innovation, leadership, and impact. 🌟🏅

Research Focus

Dr. Vijayakumar’s primary research revolves around Aquatic Toxicology and Nanobiotechnology, emphasizing the impact of engineered nanomaterials (ENMs) on aquatic ecosystems. He investigates the toxicity, transport, bioaccumulation, and ecological impact of nanoparticles, including their genotoxic and ecotoxic consequences. His research extends to drug delivery systems, exploring biocompatibility, host responses, and novel therapeutics for neurodegenerative diseases and tissue regeneration. His interdisciplinary approach bridges molecular biology, environmental science, and materials engineering. A strong advocate for eco-safe nanotechnology, he integrates in vitro, in vivo, and computational models to assess risk and functionality. His team engages in animal model studies, molecular simulations, and regenerative biomaterial design, contributing to innovations in environmental health and biomedical applications. His vision is to foster sustainable and safe biotechnological advancements for future healthcare and environmental well-being. 🌊🧪🧠

Publication Top Notes

  1. 🧬 Exploring Piperine as a Potential Treatment for Polycystic Ovarian Syndrome: Insights from In-silico Docking Studies (2024)

  2. 🐟 Toxicity Assessment on Haematology and Enzymological Alterations of Al₂O₃ Nanoparticles Exposed Freshwater Fish (2024)

  3. 🌿 Exploring Potential Anti-aging Compounds and Binding Affinity of Resveratrol with hTERT Gene (2024)

  4. 🧠 Computational Analysis of Anti-Alzheimer’s Efficacy of Myristicin from Nutmeg (2024)

  5. 🧫 Characterization of Novel Antimicrobial Peptides from Clarias Batrachus (2024)

  6. 💧 Carbon Nanoparticles Fabricated Microfilm for Microplastics Filtration (2023)

  7. 🩹 Functional 2D Graphene Oxide in the Wound Healing Process (2023)

  8. 🦐 Probiotics-Infused Withania Somnifera for Shrimp Development (2023)

  9. 🧪 Fabrication of Silver Nanoparticles using Illicium Verum and Its Anti-bacterial Activity (2023)

  10. 🍇 Pharmacological Properties and Mode of Action of Quercetin: A Bioactive Flavonoid (2023)

  11. 🌱 Anti-inflammatory Activity of Ocimum Tenuiflorum-loaded Chitosan Nanoparticles (2023)

  12. 🧬 Complete Overview of Enzymatic Responses in Nanoparticle-Stressed Fish Models (upcoming)

Elof Eriksson | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Elof Eriksson | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Prof. Dr Elof Eriksson, Harvard Medical school, United States

Dr. Elof Eriksson, MD, PhD, is an esteemed plastic surgeon and researcher, born in Sweden. He earned his MD in 1969 and a PhD in Physiology in 1972 from the University of Göteborg. After relocating to the United States in 1973, he trained in general surgery at the University of Chicago and plastic surgery at the Medical College of Virginia. He has held key academic and clinical roles, notably as Chief of Plastic Surgery at Brigham and Women’s Hospital and Children’s Hospital in Boston. In 1996, he was named the first Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School. Renowned for his pioneering work in wound healing, Dr. Eriksson also established several specialized programs, including face transplantation. After stepping down as Chief in 2016, he became Professor Emeritus. Dr. Eriksson’s legacy includes over 200 publications, 50 patents, and numerous prestigious awards in surgery and biomedical research.

Publication Profile

scopus

Education

Dr. Eriksson began his medical and scientific journey in Sweden, where he earned an MD in 1969 and a PhD in Physiology in 1972 from the University of Göteborg. His dual degree underscores his deep commitment to both clinical excellence and biomedical research. Following his move to the United States in 1973, he pursued further training in surgery, completing his general surgery residency at the University of Chicago. He then specialized in plastic surgery, finishing his residency at the Medical College of Virginia. This strong educational foundation prepared Dr. Eriksson for a distinguished international career that bridged academic medicine, clinical innovation, and research leadership. His training in both physiology and surgery uniquely positioned him to develop translational research programs in wound healing and plastic surgery that have had a global impact. His dedication to academic medicine led to his appointment as the first Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School.

Experience

Dr. Elof Eriksson has over four decades of clinical, academic, and research experience. After his U.S.-based surgical training, he returned to Sweden to serve as an attending plastic surgeon at the University of Göteborg for three years. In 1982, he became the Director of the Burn Center at Southern Illinois University, where he focused on acute care and wound management. In 1986, he was recruited to Brigham and Women’s Hospital and Children’s Hospital in Boston as Chief of Plastic Surgery, a role he held until 2016. Under his leadership, the division expanded from 1 to 19 faculty members, and he initiated groundbreaking programs in wound care, microsurgery, breast reconstruction, and face transplantation. In 1996, he was named the Joseph E. Murray Professor of Plastic Surgery at Harvard Medical School. He also served on various national boards and hospital committees, reflecting his leadership in clinical governance and academic surgery.

Awards and Honors

Dr. Eriksson’s groundbreaking contributions in plastic surgery and wound healing have earned him numerous awards and honors. He was the recipient of the Harvard Plastic Surgery Teaching Award, recognizing his excellence in academic mentorship. His lifetime achievements were celebrated with the Boswick Lifetime Achievement Award from the Symposium on Advanced Wound Care and the Lifetime Achievement Award from the Wound Healing Society. For his pioneering research, he was also honored by the American Association of Plastic Surgeons and the Plastic Surgery Foundation. Beyond accolades, he served in leadership roles including President of the Wound Healing Society and the Wound Healing Foundation, and a board member of the American Board of Plastic Surgery. His extensive service was also recognized through his appointment to the Board of Trustees at Dartmouth Hitchcock Medical Center. These honors reflect both his clinical excellence and his significant impact on translational and surgical sciences.

Research Focus

Dr. Elof Eriksson’s research focuses on wound healing, integrating basic science, translational research, and clinical innovation. He has explored advanced methodologies ranging from gene transfer techniques to strategies that regulate the wound microenvironment in response to acute trauma. His laboratory has led numerous federally funded studies, including substantial support from the National Institutes of Health (NIH) and the U.S. Department of Defense, aimed at improving wound care for trauma patients and military personnel. Dr. Eriksson’s research has significantly advanced our understanding of tissue regeneration, inflammation control, and post-injury cellular behavior. He has published over 200 peer-reviewed articles and is the first author of more than 50 patents, many of which have led to innovative therapies in clinical use. His work bridges the gap between lab research and surgical application, particularly in developing new treatments for complex wounds, burn injuries, and reconstructive surgery.

Publication Top Notes

  • “Gene transfer strategies for wound healing optimization”

  • “Modulation of wound microenvironment after acute trauma”

  • “Topical application of growth factors in burn wounds”

  • “Strategies for improving graft integration in skin reconstruction”

  • “The role of inflammation in chronic wound healing”

  • “Clinical outcomes of face transplantation procedures”

  • “Advancements in vascularized composite allotransplantation”

  • “Application of tissue-engineered scaffolds in wound care”

  • “NIH-funded translational research in acute wound management”

  • “Gene expression profiling of wound healing phases”

  • “Controlled delivery systems for wound therapeutics”

  • “Collagen remodeling and scar minimization techniques”

  • “Defense-sponsored innovations in trauma wound therapy”

  • “Multidisciplinary approaches to facial reconstruction”

  • “Clinical trials in bioengineered skin substitutes”